ONE-WAYOngoing theme · still written in the latest filings
Early approval strategy leveraging FDA RMAT designation for SB623 in the United States
A regulatory strategy to accelerate the development, approval and commercial launch of the regenerative medicine product SB623 in the United States by leveraging FDA RMAT designation.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.